Targeting CLK2 and serine/arginine‐rich splicing factors inhibits multiple myeloma through downregulating RAE1 by nonsense‐mediated mRNA decay mechanism
Cancer Science · 2025
DOI: 10.1111/cas.16387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Serine-Arginine Splicing Factors, Protein-Tyrosine Kinases, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Science and Technology Program, Science, Technology and Innovation Commission of Shenzhen Municipality.
Abstract (Originalsprache)
Multiple myeloma (MM) is closely related to abnormal RNA splicing in its pathogenesis. CDC2‐like kinase‐2 (CLK2) regulates RNA splicing by phosphorylating serine/arginine‐rich splicing factors (SRSFs), but the role of CLK2 in MM remains undefined. This study was to explore the role and mechanism of CLK2 in MM. Analyzing GEO datasets of MM patients found that high CLK2 expression predicted poor prognosis. Overexpression of CLK2 promoted the cell proliferation and cell cycle progression of MM cell ARP1 and H929. Knockdown or inhibition of CLK2 suppressed cell proliferation and induced cell apoptosis and cell cycle arrest in ARP1 and H929 cells in vitro. An MM xenograft tumor experiment showed that CLK2 overexpression promoted tumor growth, while CLK2 inhibition suppressed tumor growth in vivo. Mechanistic studies revealed that interfering CLK2 inhibited SRSF phosphorylation, and induced exon 9 skipping of RAE1 , resulting in nonsense‐mediated mRNA decay (NMD) of RAE1 . In addition, RAE1 knockdown inhibited cell proliferation in ARP1 and H929 cells. Moreover, RAE1 overexpression promoted cell proliferation and cell cycle progression of ARP1 and H929 cells, and partially reversed the antitumor effect of CLK2 knockdown. Targeting CLK2 shows antitumor effects on MM partially through inhibiting SRSF phosphorylation and inducing NMD of RAE1 . Therefore, targeting the CLK2/SRSFs/RAE1 axis could be a potential therapeutic strategy for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Yang Liu
Förderung
- Shenzhen Science and Technology Program
- Science, Technology and Innovation Commission of Shenzhen Municipality
Zitieren
APA
Liu, Y., Liao, Y., Lai, S., Wu, X., Liang, L., Zhang, Y., Wei, R., & Chen, Y. (2025). Targeting CLK2 and serine/arginine‐rich splicing factors inhibits multiple myeloma through downregulating RAE1 by nonsense‐mediated mRNA decay mechanism. Cancer Science. https://doi.org/10.1111/cas.16387
Vancouver
Liu Y, Liao Y, Lai S, Wu X, Liang L, Zhang Y, et al. Targeting CLK2 and serine/arginine‐rich splicing factors inhibits multiple myeloma through downregulating RAE1 by nonsense‐mediated mRNA decay mechanism. Cancer Science. 2025. doi:10.1111/cas.16387
BibTeX
@article{Liu2025,
author = {Liu, Yang and Liao, Yaping and Lai, Shuping and Wu, Xiaoyan and Liang, Laoqi and Zhang, Yihao and Wei, Rongfang and Chen, Yan},
title = {Targeting CLK2 and serine/arginine‐rich splicing factors inhibits multiple myeloma through downregulating RAE1 by nonsense‐mediated mRNA decay mechanism},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16387}
}
EUVIMED